Monopar Therapeutics Inc
$ 57.75
1.53%
06 Feb - close price
- Market Cap 385,919,000 USD
- Current Price $ 57.75
- High / Low $ 61.20 / 57.45
- Stock P/E N/A
- Book Value 21.25
- EPS -3.96
- Next Earning Report 2026-03-30
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.18 %
- ROE -0.26 %
- 52 Week High 105.00
- 52 Week Low 26.05
About
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company based in Wilmette, Illinois, dedicated to developing innovative therapies that enhance treatment outcomes for cancer patients. The company boasts a diverse pipeline of proprietary drug candidates, utilizing advanced formulation technologies to address critical unmet needs in oncology while prioritizing both efficacy and safety. As Monopar advances its clinical programs, it remains strategically positioned to make significant contributions to cancer care and solidify its standing within the biopharmaceutical landscape.
Analyst Target Price
$112.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-10 | 2025-08-12 | 2025-05-07 | 2025-03-26 | 2024-11-07 | 2024-08-09 | 2024-05-09 | 2024-03-28 | 2023-11-09 | 2023-08-10 | 2023-05-11 | 2023-03-23 |
| Reported EPS | -0.48 | -0.35 | -0.38 | -2.75 | -0.37 | -0.5 | -0.1 | -0.12 | -0.14 | -0.16 | -0.19 | -0.23 |
| Estimated EPS | -0.3989 | -0.09 | -0.5667 | -0.42 | -0.48 | -0.47 | -0.12 | -0.15 | -0.17 | -0.18 | -0.22 | -0.2 |
| Surprise | -0.0811 | -0.26 | 0.1867 | -2.33 | 0.11 | -0.03 | 0.02 | 0.03 | 0.03 | 0.02 | 0.03 | -0.03 |
| Surprise Percentage | -20.3309% | -288.8889% | 32.9451% | -554.7619% | 22.9167% | -6.383% | 16.6667% | 20% | 17.6471% | 11.1111% | 13.6364% | -15% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-30 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.58 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MNPR
2026-02-03 06:58:17
Monopar Therapeutics Inc. (NASDAQ:MNPR) has received an average "Buy" recommendation from thirteen brokerages, with an average 12-month price target of $107.00. Despite missing last quarter's EPS estimates, analysts forecast a negative full-year EPS of -1.65. Institutional investors have been adjusting their stakes, and the CFO recently purchased 1,500 shares.
2026-02-02 13:58:18
BTIG has reaffirmed its Buy rating for Monopar Therapeutics (MNPR) with an unchanged price target of $104.00 as of February 2, 2026. This follows other recent analyst ratings, including a Buy from Chardan Capital and an Overweight from Morgan Stanley. Monopar Therapeutics is a clinical-stage biopharmaceutical company developing therapies for cancer patients.
2026-01-30 04:31:39
Chardan Capital has reissued a "Buy" rating for Monopar Therapeutics (NASDAQ:MNPR) with a target price of $100, indicating a potential upside of 48.3% from its current price. Despite mixed analyst views, the MarketBeat consensus is also a "Buy" with an average target of $107. The article also details recent analyst adjustments, stock performance, insider buying, and institutional holdings for Monopar Therapeutics, a clinical-stage biotechnology company focused on cancer treatments.
2026-01-29 13:59:36
Chardan Capital has reaffirmed its Buy rating for Monopar Therapeutics (MNPR) with a continuous $100 price target, signaling a positive outlook. This comes amidst varying analyst opinions, including a recent downgrade by Raymond James and reinstatements of Buy ratings by other firms. The average analyst target price for MNPR is $112.00, implying a significant upside from its current price.
2026-01-28 14:02:00
This article provides an in-depth analysis of Monopar Therapeutics Inc. (MNPR) outlining a "Precision Trading" strategy based on AI models. It highlights a strong sentiment across all time horizons, an exceptional risk-reward setup, and offers three distinct trading strategies: Position Trading, Momentum Breakout, and Risk Hedging. The analysis includes specific entry zones, targets, and stop-loss levels for each strategy.
2026-01-23 18:28:33
JonesTrading analyst Soumit Roy has reaffirmed a "Buy" rating for Monopar Therapeutics (MNPR.US) and maintained a target price of $130. According to TipRanks data, Roy has a 27.5% success rate and an average return of -12.9% over the past year. Monopar Therapeutics saw a 4.22% increase in its stock (MNPR) following this announcement.
